Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02343406
Title ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications

glioblastoma

Therapies

Lomustine

Depatuxizumab mafodotin

Temozolomide

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.